RV6153   

GtoPdb Ligand ID: 10163

Synonyms: RV-6153
Compound class: Synthetic organic
Comment: RV6153 is a clinical stage PI3Kγδ inhibitor [1] that is being developed by Janssen Biotech subsidiary RespiVert. The chemical structure is claimed in patent US9227977B2 [2]. It is a derivative of RV1729. RV6153 is selective for PI3Kγδ over the α and β enzyme isoforms.
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 13
Topological polar surface area 152.43
Molecular weight 717.23
XLogP 5.88
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Canonical SMILES COCCOCCOCC#Cc1cccc2c1c(=O)n(c(n2)Cn1nc(c2c1ncnc2N)c1cc(O)cc(c1)F)Cc1ccccc1C(F)(F)F
Isomeric SMILES COCCOCCOCC#Cc1cccc2c1c(=O)n(c(n2)Cn1nc(c2c1ncnc2N)c1cc(O)cc(c1)F)Cc1ccccc1C(F)(F)F
InChI InChI=1S/C36H31F4N7O5/c1-50-12-13-52-15-14-51-11-5-8-22-7-4-10-28-30(22)35(49)46(19-23-6-2-3-9-27(23)36(38,39)40)29(44-28)20-47-34-31(33(41)42-21-43-34)32(45-47)24-16-25(37)18-26(48)17-24/h2-4,6-7,9-10,16-18,21,48H,11-15,19-20H2,1H3,(H2,41,42,43)
InChI Key JTACVHJPXOKMTI-UHFFFAOYSA-N
Immunopharmacology Comments
RV6153 is a PI3Kγδ inhibitor that was developed as a potential treatment for uncontrolled asthma and COPD. Pharmacological inhibition of PI3K γ and δ isoforms reduces airway hyper-responsiveness, IgE release, pro-inflammatory cytokine expression, inflammatory cell accumulation into the lung and vascular permeability in preclinical model systems, and this mechanism has advanced to clinical evaluation in patients with inflammatory lung conditions such as asthma and COPD.